InCode BioPharmaceutics' Series A Round

InCode BioPharmaceutics raised a round of funding on December 25, 2006. Investors include Avalon Ventures.

Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The mechanism-of-action of HC3-1496 results in enzymatic depletion of the …

Articles about InCode BioPharmaceutics' Series A Round: